Influence of perfluoroorganic emulsion on morphometric parameters of the liver in a systemic inflammatory response (experimental study)

The objective was to study the effect of drug «Oxyphtem»1 on liver morphometric parameters in a systemic inflammatory response.

Materials and methods. The experimental study was carried out on male Wistar rats (n = 26). The rats of the experimental group were injected with drug «Oxyphtem» intravenously once. Daily observation was carried out during14 days. Rats were taken out of the experiment on the 15^th day under light ether anesthesia. Liver samples were fixed in 10 % neutral formalin in phosphate buffer for 24 hours. Histological preparations were studied using the Measure Pixels image analysis computer program based on a Leica 2000 light microscope.

Results. In the intact group of rats, no violations of the liver parenchyma were detected: hepatocytes had clear boundaries, the lamellar structure was preserved and sinusoidal capillaries were not dilated. With the development of the systemic inflammatory response in the liver of rats of the control group, expansion and blood filling of the central veins and sinusoids, violation of the structure of the liver plates, and perinuclear edema of hepatocytes were noted. In the experimental group of rats with the use of drug «Oxyphtem», the preservation of the structure of the liver plates was observed, binuclear hepatocytes were found, and the sinusoids were not expanded. We hypothesize that hepatocyte proliferation and the increase in binuclear hepatic cells were indicative of the regenerative response to systemic inflammatory damage and metabolic demand.

Conclusion. The use of drug «Oxyphtem» under conditions of the experimental systemic inflammatory response increases reparative regeneration and adaptation of the liver.

1. Arshintseva E.V., Pushkin S.Yu. Comparative study of the maximum tolerant dose of perfluoroorganic emulsions. Scientific aspect, 2022, vol. 3, no. 3, pp. 288–331. (In Russ.)

2. International terms for human cytology and histology with an official list of Russian equivalents. Banin V.V., Bykov V.L., eds. Moscow, GEOTAR-Media, 2009, 272 p. (In Russ.)

3. Basov F.V., Tarasenko V.S., Demin D.B. et.al. Perftoran effect on morphofunctional changes of liver in experimental acute pancreatitis. Orenburg Medical Bulletin, 2015, vol. 3, no. 3, pp. 10–11. (In Russ.)

4. Blinkova N.B., Sazonov S.V., Leontiev S.L. Hepatocyte polyploidy in liver regeneration in chronic hepatitis in patients from different age groups. Yekaterinburg, Unika, 2017, 106 p. (In Russ.)

5. Golubev A.M., Ragimov R.M., Osmanov A.O. Use of ozonized perftoran in acute peritonitis. General resuscitation, 2005, vol. 1, no. 1, pp. 9–12. (In Russ.) DOI: 10.15360/1813-9779-2005-1-9-12.

6. Dalgatov G.D., Saburina I.N., Repin V.S. The use of cellular and x-ray endovascular technologies in combination with regional perfusion of perfluorocarbon emulsion in the treatment of chronic diffuse liver diseases. Genes and Cells, 2009, vol. 4, no. 2, pp. 76–83. (In Russ.)

7. Dgebuadze M.A., Ratiani L.R. Pathomorphological changes in the liver in the dynamics of experimental staphylococcal sepsis. International Journal of Applied and Basic Research, 2016, no. 3, p. 4, pp. 565–569. (In Russ.)

8. Dzyadzko A.M., Shcherba A.E., Rummo O.O. et. al. Paradox: liver failure «protects» the patient? (hypothesis). Transplantology, 2017, vol. 9, no. 1, pp. 52–70. (In Russ.)

9. Zhukova A.G., Sazontova T.G., Arkadyeva I.V. and others. Modulating effect of perftoran on the ratio of pro- and antioxidant systems in different organs. General resuscitation, 2006, vol. 1, no. 3, pp. 7–50. (In Russ.) DOI: 10.15360/1813-9779-2006-1-47-50.

10. Kasyanova T.R., Levitan B.N., Titarenko Yu.B. Markers of endothelial dysfunction in chronic liver diseases. Kuban Scientific Medical Bulletin, 2012, vol. 132, no. 3, pp. 70–74. (In Russ.)

11. Maevskij E.I. Possible reasons for the reactivity of perfluorocarbon emulsions. Part 1. Perftoran. Izvestiya instituta inzhenernoj fiziki, 2016, vol. 39, no. 39, pp. 79–87. (In Russ.)

12. Maevsky E.I., Golovnenkova A.E., Alekseev S.V. et.al. Perftoran. Untapped potential of medicine against COVID-19. Fundamental Research. Pharmacology, 2020, no. 21, pp. 854–869. (In Russ.)

13. Mitrokhina N.V. Morphological study in the differential diagnosis of liver pathologies. Vet Pharma, 2018, no. 2, pp. 76–82. (In Russ.)

14. Nikiforova L.R., Kryshen’ K.L., Borovkova K.E. et al. Review of preclinical models of sepsis and septic shock. Laboratory animals for scientific research, 2021, no. 4, pp. 17–28. DOI: 10.29296/2618723X-2021-04-03. (In Russ.)

15. Rybakova M.G. Sepsis: from systemic inflammatory response syndrome to organ dysfunction. Archive of Pathology, 2021, vol. 83, no. 1, pp. 67–72 (In Russ.) DOI: 10.17116/patol20218301167.

16. Tsyrkunov V.M., Andreev V.P., Kravchuk R.I. et.al. Clinical cytology of the liver: Ito stellate cells (hepatic stellate cells). J GSMU, 2017, vol. 4, no. 56, pp. 90–99. (In Russ.) DOI: 10.25298/2221-8785-2017-15-4-419-431.

17. Ackland G.L., Gutierrez D.A., Yao S.T. et al. Low-molecular-weight polyethylene glycol improves survival in experimental sepsis. Crit. Care Med, 2010, vol. 38, no. 2, pp. 629–636. DOI: 10.1097/CCM.0b013e3181c8fcd0.

18. Chaudhry S., Emond J., Griesemer A. Immune cell trafficking to the liver. Transplantation, 2019, vol. 103, no. 7, pp. 1323–1337. DOI: 10.1097/TP.0000000000002690.

19. Cienfuegos J.A., Rotellar F., Baixauli J. et. al. Liver regeneration – the best kept secret. A model of tissue injury response. Rev Esp Enferm Dig, 2014, vol. 106, no. 3, pp. 171–194.

20. Dembic Z. The Cytokines of the Immune System. The Role of Cytokines in Disease Related to Immune Response. 1st ed. Philadelphia, Elsevier, 2015, 320 p.

21. Hardy K.J., Tancheroen S., Shulkes A. Hepatic ischemia-reperfusion injury modification during liver surgery in rats: pretreatment with nifedipine or miso-prostol. Liver Transpl. Surg, 1995, vol. 5, no. 1, pp. 302–310.

22. Isozaki H., Fujii K., Nomura E. et. al. Calcium concentration in hepatocytes during liver ischaemia-reperfusion injury and the effects of diltiazem and citrate on perfused rat liver. Eur. J. Gastroenterol. Hepatol, 2000, vol. 12, no. 3, pp. 291–297.

23. Strieter R.M., Remick D.G., Ward P.A. et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem. Biophys. Res. Commun, 1988, vol. 155, no. 3, pp. 1230–1236.

24. Strnad P, Tacke F, Koch A. Liver – guardian, modifier and target of sepsis. Nat. Rev. Gastroenterol. Hepatol, 2017, vol. 14, no. 1, pp. 55–66. DOI: 10.1038/nrgastro.2016.168.

25. Uchida M., Takemoto Y., Nagasue N. et al. Effect of verapamil on hepatic reperfusion injury after prolonged ischemia in pigs. J. Hepatol, 1994, vol. 21, no. 2, pp. 217223.

26. Liver Regeneration: Basic mechanisms, relevant models and clinical applications. Udayan M. A., eds. London, Academic Press, 2015, 326 p.

27. Voelker M.T., Laudi S., Henkelmann J. et al. Extracorporeal membrane oxygenation and perfluorocarbon in a therapy refractory case of acute respiratory distress syndrome. Ann Thorac Surg, 2022, vol. 113, no. 5, pp. e355–e358. DOI: 10.1016/j.athoracsur.2021.07.045.

28. Wang C., Ma C., Gong L. et.al. Macrophage polarization and its role in liver disease. Front. Immunol, 2021, no. 12, pp. 803037. DOI: 10.3389/fimmu.2021.803037.

29. Wu X., Qian G., Zhao Y. et al. LBP inhibitory peptide reduces endotoxin-induced macrophage activation and mortality. Inflamm. Res, 2005, vol. 54, no. 11, pp. 451–457. DOI: 10.1007/s00011-005-1378-1.